Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 88

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 88
---
3 and 12                        
                                  £’000                    years             
                                             months                          
                                                           £’000             
                                             £’000                           
  Trade and other payables        1,173      –             –            –    
 ─────────────────────────────────────────────────────────────────────────────
  Lease liabilities                  49      140           188          254  
  Total                           1,222      140           188          254  

More details with regard to the line
items above are included in the respective notes:

  Trade and other payables – note 15  

  Deferred consideration – note 16  

  Borrowings – note 17  

Capital risk
management

The Group monitors capital which comprises
all components of equity (i. e. share capital, share premium, foreign exchange reserve and accumulated deficit).

The Group’s objectives when maintaining
capital are:

  to safeguard the entity’s ability to continue as a going  

  to have sufficient resource to take development projects forward  

The Group continues to incur substantial
operating expenses. Until the Group generates positive net cash inflows from the commercialisation of its products it remains dependent
upon additional funding through the injection of equity capital and government funding. The Group may not be able to generate positive
net cash inflows in the future or to attract such additional required funding at all, or on suitable terms. In such circumstances the
development programmes may be delayed or cancelled, and business operations cut back.

The Group seeks to reduce this risk
by keeping a tight control on expenditure, avoiding long term supplier contracts (other than clinical trials), prioritising development
spend on products closest to potential revenue generation, obtaining government grants (where applicable), maintaining a focussed portfolio
of products under development and keeping shareholders informed of progress.

There have been no changes to the Group’s
processes for managing capital risk since the previous year.

21 Deferred
tax

Deferred tax is calculated in full on
temporary differences under the liability method using tax rates applicable in the tax jurisdictions where the tax asset or liability
would arise.

The movement on the deferred tax account
in 2024 is £nil (2023: £nil, 2022: £nil) as the net credit arising on the amortisation of intangible assets and other
timing differences has been matched by a reduction in the deferred tax asset recognised on the losses offsetting the liability remaining.

Unused tax losses carried forward, subject
to agreement with local tax authorities, were as follows:

  Schedule of unused tax losses